Compare Eli Lilly And Co (LLY) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Vale SA — how do they compare? Eli Lilly And Co trades at $1,173.02 (market cap $1.04T), while Vale SA trades at $13.5 (market cap $57.32B). The key difference: Eli Lilly And Co is far larger — about 18.1× Vale SA's market cap, and Vale SA pays the higher dividend (8.87%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Vale SA for 109 Days on average.
| LLY | VALE | |
|---|---|---|
Market Cap | $1.04T | $57.32B |
Volume | 3,064,878 | 27,996,846 |
Sector | Health | Basic Materials |
52-Week High | $1.28K | $17.82 |
52-Week Low | $799.57 | $10.75 |
Typical Hold Time | 93 Days | 109 Days |
Enterprise Value | $1.09T | $73.56B |
Dividend Yield | 0.59% | 8.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
VALE trades at $13.50, down 0.81% with bearish technical signals. The stock has missed earnings expectations for three consecutive quarters, with Q3 2026 EPS expected at $0.42. Revenue declined from $43.8B in 2022 to $38.4B in 2025, though 2026 projections show a slight recovery to $41.2B. Analyst consensus is mixed with 32% buy ratings but a $16.21 price target suggesting 20% upside. Recent news highlights cost pressures and regulatory risks in Brazil.
VALE faces headwinds from declining iron ore margins and rising operational costs, but maintains strong cash flow and dividend payments. The base metals segment shows growth potential, though cyclical exposure and Brazilian regulatory uncertainty pose significant risks. With current valuation metrics appearing reasonable (P/E 26.8, P/B 1.5), the stock offers value for patient investors willing to navigate commodity volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
